Sugi Predict

Sugi Predict / Compounds / SCHEMBL6058321

SCHEMBL6058321

SCHEMBL6058321

Cc1cc(C)c(NC(=O)c2ccc3nc(NC(=O)Cc4ccc5c(c4)OCO5)sc3c2)c(C)c1

nearest known ligand 0.64

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.64
▸ NPC1 O15118 3/20 0.64
▸ SMN1; SMN2 Q16637 3/20 0.64
▸ ALDH1A1 P00352 2/20 0.64
▸ HPGD P15428 2/20 0.64
▸ RAB9A P51151 2/20 0.64
▸ LCK P06239 16/20 0.61
▸ PKM P14618 1/20 0.56
▸ MEN1 O00255 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ NFKB1 P19838 1/20 0.53
▸ NFKB2 Q00653 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ RELA Q04206 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6058324 0.93 LCK (0.62) KDM4ENPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL6057946 0.92 KDM4E (0.61) KDM4ENPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL6058087 0.88 LCK (0.72) KDM4ENPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL6057725 0.85 LCK (0.59) KDM4ENPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL6058198 0.84 LCK (0.70) KDM4ENPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL6058058 0.84 LCK (0.66) LCK
SCHEMBL6057780 0.84 LCK (0.68) LCK
SCHEMBL774617 0.83 LCK (0.56) NPC1SMN1; SMN2HPGDRAB9ALCK
SCHEMBL6058230 0.81 LCK (0.78) LCK
SCHEMBL6058128 0.81 LCK (0.63) LCKKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1037632-B1 BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2006-01-11 — — EP claimed
US-6825355-B2 FOR THERAPY OF IMMUNOLOGIC DISORDERS SUCH AS TRANSPLANT REJECTION, RHEUMATOID ARTHRITIS. MULTIPLE SCLEROSIS, INFLAMMATORY BOWEL DISEASE, LUPUS, GRAFT VS. HOST DISEASE BRISTOL-MYERS SQUIBB CO. 2004-11-30 — — US claimed
US-20020123484-A1 Benzothiazole protein trosine kinase inhibitors DAS JAGABNDHU (US) 2002-09-05 — — US claimed
US-6825355-B2 FOR THERAPY OF IMMUNOLOGIC DISORDERS SUCH AS TRANSPLANT REJECTION, RHEUMATOID ARTHRITIS. MULTIPLE SCLEROSIS, INFLAMMATORY BOWEL DISEASE, LUPUS, GRAFT VS. HOST DISEASE BRISTOL-MYERS SQUIBB CO. 2004-11-30 — — US disclosed
EP-1037632-A4 BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2002-08-21 — — EP disclosed
EP-1037632-A1 BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2000-09-27 — — EP disclosed
WO-1999024035-A1 BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 1999-05-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020123484-A1 Benzothiazole protein trosine kinase inhibitors TXK, LTK, JAK2 KDM4E 1679/4885NPC1 2700/4885SMN1; SMN2 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.